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INTRODUCTION
Pancreatic cancer is one of the most
virulent malignances with an overall
five-year survival rate of only 3–5% and
a median survival time after diagnosis
of < 6 months (1). Despite this immense
clinical problem, pancreatic cancer biol-
ogy remains poorly understood in com-
parison with other cancers. For in-
stance, although it has been recognized
for almost 40 years that transformed
cells display a disturbed actin cyto-
skeletal structure, the mechanisms me-
diating disturbed actin filament organi-
zation in pancreatic cancer remain
largely obscure.
Among the mechanisms that mediate
deviant cytoskeletal structure in cancer
cells is an aberrant expression of gelsolin.
Gelsolin is a Ca2+- and polyphosphoinosi-
tide 4, 5-bisphosphate (PIP2)-regulated
actin filament severing and capping
protein (2). Gelsolin was first isolated
from rabbit lung macrophages as a mod-
ulator of the cytoplasmic actin gel-sol
transformation (3), and is generally con-
sidered one of the most important regu-
lators of the actin cytoskeleton (4). Thus,
gelsolin is an obvious candidate for ex-
plaining altered cytoskeletal reorganiza-
tion in pancreatic cancer. In support for
such a notion, diminished expression
and even silencing of the gelsolin gene
has been documented in many types of
human cancers, including bladder,
breast, lung, prostate, gastric, and ovar-
ian cancers (5–10). Strikingly, forced ex-
pression of gelsolin can cause cancer cell
morphological reversion and greatly re-
duce colony-forming ability in vitro, as
well as tumorigenicity in vivo in various
tumor types (11). However, downregula-
tion of gelsolin protein levels in pancre-
atic cancer has not been demonstrated
convincingly, nor have the molecular
mechanisms that could mediate such
downregulation been identified.
In the present study, we provide con-
vincing evidence that gelsolin protein
levels become severely downregulated in
pancreatic cancer. This downregulation
differs from most other tumor types be-
cause the downregulation is not mirrored
at the mRNA level, apparently excluding
pretranslational mechanisms. In apparent
agreement, we see that gelsolin is specifi-
cally routed into the ubiquitination-
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proteasome system and that inhibition of
this system, at least in vitro, is sufficient
to restore gelsolin protein levels. Thus,
downregulation of gelsolin is an intrinsic
part of the pancreatic cancerous process
which, unique to this type of cancer,




Fresh tissue samples of 11 pancreatic
ductal adenocarcinomas and their corre-
sponding distant normal counterparts
were obtained at the time of resection
with informed consent from Cancer In-
stitute and Hospital (CIH), Chinese
Academy of Medical Sciences (CAMS),
and Peking Union Medical College
(PUMC) between November 2001 and
March 2003. The samples were snap-
frozen in liquid nitrogen before storage
at –80° C. None of them received preop-
erative radiotherapy or chemotherapy.
Formalin-fixed paraffin-embedded tis-
sue blocks containing pancreatic cancer
and normal pancreatic tissue were col-
lected from the archives of the Depart-
ments of Surgery at CIH, CAMS, and
PUMC between January 1991 and Au-
gust 2002, and subjected to tissue mi-
croarray construction. The relevant 
ethical committee approved of the inves-
tigations performed.
Cell Culture and Drug Treatment
Human pancreatic adenocarcinoma
cell line BxPC-3 was obtained from
American Type Culture Collection
(Manassas, VA, USA). BxPC-3 cells
were cultured in RPMI 1640 medium
supplemented with 10% heat-inacti-
vated fetal bovine serum, 100 U mL–1
penicillin, and 100 μg/mL streptomycin
at 37° C in 5% CO2. Specific proteasome
inhibitor lactacystin (Sigma-Aldrich, St.
Louis, MO, USA) was dissolved in di-
methyl sulfoxide (DMSO). Cells were
seeded on 100 mm plates. After 70% to
90% confluent, cells were treated with
10 μM lactacystin in serum-free me-
dium for the indicated times. Cells were
treated with 0.1% DMSO as a vehicle
control.
Antibody Microarray Detection
Procedure and Data Analysis
Antibody microarrays (BD Clontech
380, Cat. K1847-1, Lot. 2070683) were
obtained from BD Biosciences Clontech
(Palo Alto, CA, USA), and sample prepa-
ration and processing procedures were
performed as described in the antibody
microarray user manual. Briefly, to re-
duce the influence of biological heteroge-
neity among tumor samples derived
from different patients, 200 mg from each
of seven pancreatic ductal adenocarci-
noma samples were pooled together and
pulverized using liquid nitrogen. An
equivalent pool was made from matched
normal pancreas. Total protein was ex-
tracted from 200 mg of pooled cancer
sample or pooled normal pancreas using
extraction/labeling buffer, and then
mixed with Cy3 or Cy5 (Amersham Bio-
sciences, Piscataway, NJ, USA) sepa-
rately. To prevent skewing of the array
results, cancer sample (C) and normal
sample (N) were each split into two
equal portions. Each portion was then la-
beled with either Cy3 or Cy5 to produce
four samples: C-Cy3, C-Cy5, N-Cy3, and
N-Cy5. There are two same slides in the
kit. C-Cy5 (40 μg) and N-Cy3 (40 μg)
were mixed and added to slide 1, and
N-Cy5 (40 μg) and C-Cy3 (40 μg) were
mixed and added to slide 2. Following
30 min incubation at room temperature,
the slides were washed, dried, and
scanned using the GenePix 4000B Mi-
croaray Scanner (Axon Instruments,
Union City, CA, USA). There are 768
spots in this antibody microarray. Each
antibody is arrayed by duplicate spots
side-by-side on the slide. Besides the an-
tibody capture-dependent spots, there
are four paired spots pre-labeled with
Cy3 and Cy5 bovine serum albumin
(BSA) located near the outermost corners
of the printed area that serve as orienta-
tion markers. Two paired BSA spots,
not labeled with fluorophore, serve as
negative controls. Therefore, this slide
contains 378 different antibodies.
Primary data collection and analysis
were carried out using the GenePix Pro
4.0 (Axon Instruments) software pack-
age. The antibody spot was excluded
from further analysis if it had a signal:
background ratio of < 1.5 in both chan-
nels. For each spot, the median of ratios
was used in subsequent analysis. The
data were imported into the BD Clontech
Ab Microarray Analysis Workbook. The
relative fluorescence units of C-Cy5/N-Cy3
from slide 1 (ratio 1) and N-Cy5/C-Cy3
from slide 2 (ratio 2) were calculated
and an internally normalized ratio (INR)
was obtained by computing the square
root of ratio 1/ratio 2. This value repre-
sents the abundance of an antigen in
pancreatic cancer relative to that of nor-
mal pancreas. The value of INR > 1.5 or
< 0.7 was considered as a significantly
different protein expression level be-
tween the two samples.
Measurement of Gelsolin mRNA
Expression by Semiquantitative
Reverse Transcriptase-PCR
Total RNA was isolated from pancre-
atic cancer specimens (n = 9) and their
corresponding distant normal counter-
parts and cell line BxPC-3 using RNeasy
MinElute cleanup kit (QIAGEN, Valen-
cia, CA, USA) according to the manufac-
turer’s instruction. RNA quality was as-
sessed on agarose gel electrophoresis
and spectrophotometric analysis. Re-
verse transcription (RT) reactions were
performed on 5 μg of total RNA using
SuperScript First-Strand synthesis for
RT-PCR II kit (Invitrogen, Carlsbad, CA,
USA) at 42° C for 80 min, and 0.5–1 μg
aliquots of the cDNA then were sub-
jected to RT-PCR. The specific gelsolin
primer sequences were used as follows:
5’-CCACTGCGTCGCGGGG-3’ (sense)
and 5’-GGCAGCCAGCTCAGCCATG-3’
(antisense). The PCR step was performed
using Taq DNA polymerase (Invitrogen).
As an internal control, GAPDH was am-
plified to ensure cDNA quality and
quantity for each RT-PCR reaction. Band
intensity was quantified using Quantity
One 4.4.1 software (Bio-Rad Laboratories
Inc, Hercules, CA, USA).
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Western Blot
Total tissues (n = 11) and cell lysates
were prepared in extraction buffer con-
taining 50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1% Triton-100, 0.1% SDS, 1 mM
EDTA, 1 mM AEBSF, 20 μg/mL apro-
tinin, and 20 μg/mL leupeptin. Equal
amounts of total protein (10 μg) were
separated by 10% SDS-PAGE and trans-
ferred to Hybond-P polyvinylidene diflu-
oride (PVDF) membrane (Amersham
Pharmacia Biotech, Piscataway, NJ,
USA). After blocking with 5% nonfat dry
milk in PBS with 0.1% Tween-20, mem-
branes were probed with mouse anti-
gelsolin monoclonal antibody (1:1000
dilution in PBS; BD Biosciences Pharmin-
gen, San Diego, CA, USA), followed by
subsequent incubation with horseradish
peroxidase-conjugated goat anti-mouse
secondary antibody (1:3000 dilution in
PBS, Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Visualization of the
protein bands was performed by the
enhanced chemiluminescence kit (Santa
Cruz Biotechnology). Parallel Western
blot was probed with an anti-α-tubulin
monoclonal antibody (Santa Cruz
Biotechnology) as a loading control.
Band intensity was quantified using
Quantity One 4.4.1 software (Bio-Rad).
Immunohistochemistry
Pancreatic cancer tissue microarray was
constructed as previously described (12),
with a total of 256 tissue spots consisting
of 32 pancreatic ductal adenocarcinomas,
6 mucinous adenocarcinomas, 4 acinar
cell carcinomas, 7 islet cell carcinomas,
8 carcinomas of the ampulla of Vater,
and 38 normal pancreatic tissues. The
streptavidin-peroxidase method was
used for the immunostaining of gelsolin.
Briefly, after deparaffinization in xylene
and rehydration in grade ethanol, en-
dogenous peroxidase activity was blocked
by incubation in 3% hydrogen peroxide
for 10 min. Tissue sections then were
heated at 100° C in 10 mM pH 6.0 citrate
buffer for 10 min to retrieve antigens.
After incubation with mouse anti-gelsolin
monoclonal antibody, gelsolin immunos-
taining was detected by adding biotiny-
lated anti-mouse secondary antibody and
streptavidin-horseradish peroxidase
(Zymed Laboratories, South San Fran-
cisco, CA, USA). 3, 3’-Diaminobenzidine
was used as a chromogen, and hema-
toxylin was used for counterstaining.
Immunoprecipitation
Total tissue and cell extracts were
lysed with lysis buffer (25 mM Tris-HCl
[pH 7.5], 150 mM NaCl, 1% NP-40, 
1 mM EDTA, 1 mM sodium orthovana-
date) containing protease inhibitors 
1 mM PMSF, 1 mM AEBSF, 10 μg/mL
aprotinin, and 10 μg/mL leupeptin.
After centrifugation, the clarified super-
natant was collected, and protein con-
centration was determined by Bradford
method. Whole cell lysate containing 
Table 1. Differentially expressed proteins in pancreatic ductal adenocarcinoma compared with normal pancreas detected by antibody
microarray.
Upregulated in pancreatic cancer Downregulated in pancreatic cancer
Name Function Name Function
UbcH6 (ubiquitin- E2 ubiquitin-conjugating DCC (deleted in colorectal Tumor suppressor gene
conjugating enzyme H6) enzyme carcinoma)
GABA b R2 (γ-aminobutyric G-protein-coupled HPV-16 L1 (human papillomavirus Human papillomavirus type 16 capsid 
acid type B receptor, receptor 51 type 16 capsid protein L1) protein L1
subunit 2)
Plakophilin 2a Diverse roles in desmosomes RACK1 (receptor for activated Receptor of activated PKC
and β-catenin signaling C kinase 1)
Inhibitor 2 Inhibit the activity of Gelsolin Actin filament regulatory protein
protein phosphatase 1
Nestin Intermediate filament Rabaptin-5 Effector of the small GTPase Rab 5
protein
ShcC Shc family protein, DBP2 (DEAD box protein 2) RNA helicase involved in pre-mRNA 
regulation of Ras pathway splicing
PRK2 (protein-kinase The Serine/threonine family IKKα/1 (inhibitor of nuclear factor Serine/threonine kinase, active NF-kα
C-related kinase 2) of protein kinase, PKC kappa-B kinase α subunit)
subfamily
Neurogenin 3 Transcription factor, c-Cbl Proto-oncogene, E3 ubiquitin-protein 
mediate neuronal ligase
differentiation
STAT 3 (signal transducer Transcription activator FXR2 (fragile × mental retardation RNA binding protein
and activator of syndrome related protein 2)
transcription 3)
NHE-3 (Na+/H+ exchanger 3) Regulation of Na+/H+ SRP54 (signal recognition particle Route proteins from the cytosol to the ER
homeostasis 54 kDa protein)
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10 μg of protein from each sample was
prepared for Western blot analysis using
anti-gelsolin antibody. For gelsolin im-
munoprecipitation analysis, 1 ml of cell
lysate corresponding to 0.5 mg of total
cellular protein first was precleared by
incubating with protein G-agarose
beads (Roche Diagnostics, Mannheim,
Germany) at 4° C for 1 h. The collected
supernatant was then incubated at 4° C
with 1.5 μg of mouse anti-gelsolin
monoclonal antibody or nonimmune
mouse IgG (Zhongshan Biotechnology,
Beijing, China) for overnight with rota-
tion. The immune complex was precipi-
tated by incubation with 30 μL of
protein G-agarose for 3 h at 4° C. The
agarose beads were pelleted by centrifu-
gation and washed three times with
lysis buffer. The beads were suspended
in 2×Laemmli sample buffer and boiled
for 10 min. Protein G-agarose beads
were removed from the complex by cen-
trifugation at 10,000g for 5 min. The su-
pernatant was loaded onto 10% SDS-
PAGE for Western blot analysis with
monoclonal antibody to gelsolin and
ubiquitin (Santa Cruz Biotechnology).
Statistical Analysis
Statistical analysis was performed
using the SPSS 11.5 software package
(SPSS, Chicago, IL, USA). The Student 
t test was used to determine the statis-
tical significance of Western blot or 
RT-PCR band intensity. Values were ex-
pressed as mean ± SD of at least three ex-
periments. The chi-square test was used
to assess the difference of gelsolin expres-
sion among different groups scored by
immunohistochemistry. The correlation
between gelsolin and each variable was
assessed with the Spearman Rank correla-




In an effort to obtain insight into the
molecular mechanisms that govern aber-
rant cytoskeletal structure in pancreatic
cancer, we compared the holo-proteome
of pancreatic cancer tissue to normal tis-
sue of the same patients on antibody
capture-based proteomic chips. As this
methodology is strongly biased toward
highly expressed proteins, it is particu-
larly useful to identify differential ex-
pression of cytoskeletal components,
which is the most abundant class of pro-
teins in the cellular proteome. Impor-
tantly, we did observe significant differ-
ences in the protein levels of some
cytoskeletal components (Table 1), but
gelsolin especially was strongly down-
regulated in pancreatic cancer. As gel-
solin is an obvious candidate to regulate
the aberrant cytoskeletal structure, fur-
ther experiments were initiated to estab-
lish whether reduced gelsolin expression
is a bona-fide candidate mechanism for
explaining disturbed cytoskeletal organi-
zation in pancreatic cancer.
The Expression of Gelsolin mRNA and
Protein in Pancreatic Cancer Tissues
and Cell Line
A supportive role for reduced gelsolin
levels in pancreatic cancer includes ob-
servations that downregulation of gel-
solin mRNA, via various genetic mecha-
nisms, is an important characteristic of
many tumor types. Whether gelsolin
mRNA also is downregulated in ductal
pancreatic cancer had not been investi-
gated, prompting studies into whether
the observations made using the anti-
body capture chips can be confirmed
using conventional technology. To de-
tect the alterations of gelsolin mRNA
and protein expression, the total RNA
and protein were extracted from the
pancreatic cancer cell line, pancreatic
ductal adenocarcinoma tissues, and
their corresponding distant normal pan-
creatic tissues. Gelsolin mRNA was de-
termined by RT-PCR method with cyto-
plasm gelsolin gene full-length specific
primers (from 96 bp to 2,360 bp). Ampli-
fication products were analyzed by 1%
agarose gel electrophoresis. Gelsolin
mRNA can be detected in these extracts.
No significant difference was observed
between nine matched pancreatic cancer
tissues and normal pancreas (P > 0.05).
Representative electrophoretic analyses
of the RT-PCR products of gelsolin and
control GAPDH are shown in Figure 1A
and 1B.
Importantly, however, gelsolin protein
levels are diminished substantially in
ductal pancreatic cancer. Protein extracts
from pancreatic tissues and cell cultures
were prepared for Western blot analysis
using monoclonal anti-gelsolin antibody.
This antibody can detect specific bands
migrating at 90 kDa. Western blot re-
vealed that 73% (8/11) of pancreatic
Figure 1. The expression of gelsolin mRNA and protein in pancreatic cancer. (A,C) Repre-
sentative RT-PCR gel and Western blot. (B,D) Band intensity was quantified using Quantity
One software. The expression of GAPDH and α-tubulin was examined as an internal con-
trol. Results are expressed as the mean ± SD of three separate experiments. *P < 0.05,
compared with their corresponding cancer samples. C, pancreatic ductal adenocarci-
noma tissues; N, corresponding distant normal pancreatic tissues; BxPC-3, pancreatic
cancer cell line.
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ductal adenocarcinoma tissues showed
extremely low or undetectable expres-
sions of gelsolin compared with
matched normal pancreatic tissues (P <
0.05). There was a weak gelsolin expres-
sion in pancreatic cancer cell line BxPC-3
(Figure 1C,1D). Thus downregulation of
gelsolin is a feature of pancreatic cancer,
but this effect seems to involve a non-
classical post-transcriptional effect.
The Correlation of Gelsolin Expression
with Clinicopathologic Factors of
Pancreatic Cancer
Downregulation of gelsolin protein
was confirmed by immunohistochem-
istry. We carried out immunohistochem-
ical studies for gelsolin on the paraffin-
embedded pancreatic cancer tissue
microarray (Figure 2). In the normal
pancreas, there were diffuse strong cyto-
plasmic immunostaining for gelsolin in
duct cells and acinar cells, but occasion-
ally nuclei appeared to stain. The posi-
tive expression rate of gelsolin in normal
pancreas was 71% (27/38). In contrast,
gelsolin expression in pancreatic adeno-
carcinoma was reduced significantly 
(χ2 = 14.41, P < 0.0001), and only 29%
(12/42) pancreatic adenocarcinomas
were scored as positive for gelsolin ex-
pression. There were no obvious differ-
ences among ductal adenocarcinoma
(31%, 10/32), mucinous adenocarcinoma
(17%, 1/6), acinar cell carcinoma (25%,
1/4), and islet cell carcinoma (43%, 3/7)
(P = 0.758). However, it was found that
the positive expression rate of gelsolin
in pancreatic ductal adenocarcinomas
with lymph node metastasis (71.4%,
5/7) increased markedly (χ2 = 6.28, P =
0.02) compared with negative lymph
node types (20%, 5/25). There were no
statistically significant correlations be-
tween gelsolin expression and histologi-
cal differentiation of pancreatic ductal
adenocarcinoma (χ2 = 0.283, P = 0.868).
Further experiments were initiated to
investigate the molecular mechanisms
mediating downregulation of gelsolin
expression in the absence of reduced
mRNA levels.
Effect of Proteasome Inhibitor
Lactacystin on the Gelsolin Expression
in Pancreatic Cancer Cells
An obvious explanation for reduced
gelsolin levels in pancreatic cancer de-
spite equal levels of gelsolin mRNA is
that gelsolin is targeted efficiently for
degradation to proteasome in pancreatic
cancer. To test this possibility directly, we
employed the BxPC-3 pancreatic cancer
cell line as model for in vivo pancreatic
cancer that is accessible to pharmacologic
manipulation by proteasome inhibitors.
Importantly, we observed that when the
BxPC-3 cell line was treated with spe-
cific 26s proteasome inhibitor lactacystin
(10 μM), gelsolin expression quickly in-
creased as compared with DMSO vehicle
control (P < 0.05), and markedly in-
creased gelsolin levels being evident
from 12 h of treatment onwards (P <
0.01) (Figure 3). Thus it seems that the
proteasome is indeed an important factor
in pancreatic cancer cells regulating sta-
bility of gelsolin proteins.
Gelsolin Protein Undergoes
Ubiquitination in Pancreatic Cancer
Degradation by the proteasome is
thought to be triggered by the polyubiq-
uitination of a target protein. To deter-
mine whether the proteasome-mediated
degradation of gelsolin is accompanied
by increased levels of poly-ubiquitinated
gelsolin, we investigated the ubiquitina-
tion status of gelsolin in extracts of pan-
creatic cancer cell BxPC-3 treated in the
absence or presence of lactacystin (10 μM,
12 h treatment). Upon subsequent im-
munoprecipitation with an anti-gelsolin
antibody, followed by Western blot using
monoclonal ubiquitin antibody and gel-
solin antibody, polyubiquitinated gel-
solin is clearly visible in BxPC-3 cell ex-
Figure 2. Immunohistochemical analysis of
gelsolin expression on pancreatic cancer
tissue microarray. (A,B) Overview of the H&E
staining and gelsolin immunohistochemical
staining on pancreatic cancer tissue micro-
array. (C) (200×) and (D) (400×) The gelsolin
expression in normal pancreas. (E) (200×)
and (F) (400×) The gelsolin expression in
pancreatic ductal adenocarcinoma with-
out lymph node metastasis. (G) (200×) and
(H) (400×) The gelsolin expression in pancre-
atic ductal adenocarcinoma with lymph
node metastasis.
Figure 3. Effect of proteasome inhibitor
lactacystin enhances the gelsolin expres-
sion. BxPC-3 cells were treated with pro-
teasome inhibitor lactacystin, DMSO or
serum-free vehicle control for 12 h, 24 h, or
48 h. (A) After incubation, lysates were
prepared and an equal amount of pro-
tein (10 μg) from each lysate was ana-
lyzed by Western blot for gelsolin. Arrow at
90 kDA indicates gelsolin. Arrow at 54 kDA
indicates α-tubulin. (B) Band intensity was
quantified by Quantity One software.
α-Tubulin was examined as an internal
control. Results are expressed as the
mean ± SD of three separate experiments.
*P < 0.05, compared with DMSO controls
of each group treated with lactacystin.
**P < 0.01, compared with 0 h control of
each group treated with lactacystin.
R E S E A R C H  A R T I C L E
M O L  M E D  1 4 ( 9 - 1 0 ) 5 8 2 - 5 8 9 , S E P T E M B E R - O C T O B E R  2 0 0 8  |  N I  E T  A L . |  5 8 7
tracts (Figure 4). Thus, the proteasome-
dependent degradation of gelsolin in this
pancreatic cancer cell is accompanied by
a high level of ubiquitin ligase activity
toward gelsolin in an experimental sys-
tem. Subsequently, experiments were
initiated to ascertain whether a similar
mechanism is operative in pancreatic
cancer in vivo.
Immunohistochemical results show
that gelsolin expression in pancreatic
cancer with lymph node metastasis is
higher than that observed in negative
lymph node metastasis (see above). In
apparent agreement, Western blot analy-
sis of fresh pancreatic cancer tissue with
and without lymph node metastasis
shows re-expression of gelsolin in the ad-
vanced lymph node positive phase of the
disease. Levels of gelsolin protein, not
mRNA, in pancreatic cancer with lymph
node metastasis (n = 3) are higher than
those in negative lymph node metastasis
(n = 8) (P < 0.05) (Figure 5A,5B), corrobo-
rating the immunohistochemical results.
Strikingly, when we immunoprecipitate
gelsolin protein of the pancreatic cancer
tissues with and without lymph node
metastasis by anti-gelsolin antibody, and
analyze its ubiquitin status, we find
downregulation of ubiquitin ligase activ-
ity toward gelsolin in pancreatic cancers
with lymph node metastasis conditions.
(Figure 5C). This provides further sup-
port for the notion that gelsolin protein
levels are controlled by the extent of
ubiquitin ligase activity toward gelsolin
in pancreatic cancer.
DISCUSSION
One of the most fundamental charac-
teristics of malignant and transformed
cells is the aberrant organization of the
cytoskeleton (13). The mechanisms
which mediate transformation-associated
cytoskeletal organization are only partly
understood (14). Here we present evi-
dence based on proteomic comparison,
immunohistochemistry, and classical
biochemistry that diminished expres-
sion of gelsolin through a transcription-
independent ubiquitination-dependent
mechanism is involved. Gelsolin is one
of the most important actin structure-
regulating proteins, and its expression in
almost all eukaryotic cells is testimony
to its fundamental importance in main-
taining an organized actin cytoskeleton
(15,16). The physiological functions of
the 90kDa gelsolin protein are regulated
by the intracellular Ca2+ concentration
and by its binding to diphosphoinosi-
tides, both of which serve to activate its
actin-severing potential, capping the
barbed ends, and promoting nucleation
of polymerization (17). In many can-
cers, gelsolin downregulation has been
identified as a factor mediating aberrant
cytoskeletal organization, substantially
reduced levels, for instance, in 77.8%
(14/18) of bladder cancers (5), 70%
(21/30) of breast cancers (6), 55%
Figure 4. Detection of gelsolin-ubiquitin conjugates. BxPC-3 cells were exposed to lacta-
cystin or DMSO vehicle for 12 h. Equal amounts of whole cell lysates were subjected to
immunoprecipitation with anti-gelsolin antibody or nonimmune mouse IgG, followed by
Western blot (WB) with anti-gelsolin antibody to detect unmodified gelsolin (A) or with
anti-ubiquitin antibody to detect gelsolin-ubiquitin conjugates (B).
Figure 5. Correlation of gelsolin protein lev-
els with pancreatic cancer lymph node
metastasis. (A) Representative Western blot
analysis of pancreatic cancer tissues with
and without lymph node (LN) metastasis.
Arrow at 90 kDA indicates gelsolin. Arrow at
54 kDA indicates α-tubulin. (B) Band inten-
sity was quantified using Quantity One soft-
ware.α-Tubulin serves as an internal con-
trol. (C) Gelsolin protein in the pancreatic
cancer tissues with and without lymph
node metastasis is immunoprecipitated (IP)
by anti-gelsolin antibody, and then Western
blot (WB) analyzes the ubiquitin-tagged
gelsolin with anti-ubiquitin antibody. Bracket
indicates gelsolin-Ub conjugates.
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(48/68) of non-small cell lung cancers
(NSCLC) (7), 68.1% (15/22) of gastric
cancers (9), and 85% (64/75) of ovarian
cancers (10). In this study, pancreatic
cancer also is added to the growing list
of malignancies displaying reduced gel-
solin protein levels, gelsolin expression
being diminished in 71% (30/42) of the
cases of pancreatic cancer as compared
with matched control tissue.
Nevertheless, the mechanisms mediat-
ing diminished gelsolin expression in
different cancer cells are not very clear.
It has been reported that there were no
major mutations, gross rearrangements,
or deletions in the coding sequence of
the gelsolin gene in human breast cancer
and NSCLC cells (6,7). Recently, Noske et
al. found inactivation of gelsolin might
be mediated by epigenetic modification
(methylation and histone deacetylation)
in human ovarian carcinoma (10). We
observed, however, gelsolin protein, but
not mRNA, was downregulated in pan-
creatic cancer. Thus, an alternative non-
classical mechanism might mediate this
downregulation. The high activity of
ubiquitin-proteasome machinery toward
gelsolin observed in the present study
seems to provide an appealing explana-
tion for the gelsolin degradation. To test
this hypothesis, we use specific protea-
some inhibitor lactacystin to inhibit the
ubiquitin-proteasome pathway in the
pancreatic cancer cell line. It was found
that a proteasome inhibitor could in-
crease the levels of gelsolin protein. Im-
munoprecipitation results showed that
gelsolin conjugated with ubiquitin in
pancreatic cancer cells. The ubiquitin-
conjugated forms of gelsolin protein
were increased after treatment with pro-
teasome inhibitor lactacystin. Taken to-
gether, these results indicate that gelsolin
protein might be ubiquitinated in pan-
creatic cancer and degraded by the ubiq-
uitin-proteasome pathway.
Importantly, later in the transforma-
tion sequence, gelsolin expression in-
creases again, as suggested by our obser-
vation that lymph node positive
pancreatic cancers react stronger toward
anti-gelsolin antibodies as compared
with lymph node negative pancreatic
cancers. This result is consistent with an
earlier study of Thomson et al. (18), who
already reported increased gelsolin ex-
pression in lymph node positive cancers
and would suggest that the expression
of the putative gelsolin-specific ubiquitin
ligase active in the earlier phases of the
transformation process is lost at later
stages. In this respect, pancreatic cancer
would resemble gastric cancer, where,
in earlier stages of the disease, Smad4-
specific ubiquitin ligases seem impli-
cated in disease progression, but where
their expression is lost at later stages of
the disease, possibly as a consequence of
the increased genetic instability at these
later stages (19). In apparent agreement,
Thompson et al. reported that high levels
of nuclear gelsolin were associated with
reduced patient survival times, which
was an independent prognostic parame-
ter for pancreatic cancer (18). Thus, re-
emergence of gelsolin expression would
be associated with the most advanced
aggressive stages of the disease.
In earlier stages of pancreatic cancer,
loss of gelsolin expression may well be
important. It was found that transfection
of the human bladder cancer cell line
UMUC-2 using exogenous full-length
gelsolin cDNA inhibited cell growth,
reduced the colony-forming ability and
the tumorigenicity in vivo. The cell cycle
of bladder cancer cells was arrested or
delayed at the G2/M phase after these
cells were transduced with recombinant
adenovirus encoding wild-type gelsolin
(Ad-GSN) in vitro. In the orthotopic blad-
der cancer model, the mass of the tumor
was approximately 90% less in Ad-GSN
treated animals than in controls.11 Thus,
for increasing the size of the transformed
compartment, lower gelsolin expression
may well be an important factor. At later
stages, re-expression of gelsolin may
help the tumor with forming metastases.
In human pancreatic adenocarcinoma
cell lines, RNA interference was used to
reduce gelsolin protein levels with two
gelsolin-targeting small interfering RNAs
(siRNAs), GSN 1 and GSN 2. In transloca-
tion assays using Boyden-style chambers,
GSN 1 and GSN 2 siRNAs significantly
reduced cell motility. In wound-healing
assays, both GSN 1 and GSN 2 siRNAs
significantly impaired the ability of
pancreatic cancer cells to migrate into
the wounded monolayer (18). These re-
sults demonstrated that gelsolin might
contribute to the motility of pancreatic
cancer cells.
In conclusion, our results show signifi-
cantly lower levels of gelsolin protein in
the early stages of human pancreatic
adenocarcinoma. This reduction of gel-
solin protein seems dependent on the
ubiquitin-proteasome-dependent degra-
dation of gelsolin in the pancreatic can-
cer cell, defining a novel pathway for
such downregulation in cancer. Study
of the correlation between proteasome-
mediated gelsolin degradation and pan-
creatic cancer progression should have
important clinical significance in the di-
agnosis, treatment, and prognosis of
human pancreatic and other cancers.
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